ProCE Banner Activity

A CARES Package in Canada? Lessons From Africa on Long-Acting Cabotegravir Plus Rilpivirine

Conference Coverage
Clinical Thought

CARES study 48-week data on long-acting cabotegravir plus rilpivirine demonstrated noninferiority and significantly increased treatment satisfaction compared with standard oral antiretroviral therapy. Learn how the data presented at CROI 2024 will affect the clinical practice of healthcare professionals in Canada who treat people living with HIV.

Released: April 02, 2024

Expiration: April 01, 2025

Share

Faculty

Marissa Becker

Marissa Becker, MSc, MD, FRCPC

Professor
Department of Community Health Sciences
Director, Technical Collaborations, Institute for Global Public Health
Rady Faculty of Health Sciences
University of Manitoba
Winnipeg, Canada

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Marissa Becker, MSc, MD, FRCPC

Professor
Department of Community Health Sciences
Director, Technical Collaborations, Institute for Global Public Health
Rady Faculty of Health Sciences
University of Manitoba
Winnipeg, Canada

Marissa Becker, MSc, MD, FRCPC, has no relevant financial relationships to disclose.